Clinical Applications of Radiomics in Nuclear Medicine.

Klinische Anwendungen von Radiomics in der Nuklearmedizin.

Journal

Nuklearmedizin. Nuclear medicine
ISSN: 2567-6407
Titre abrégé: Nuklearmedizin
Pays: Germany
ID NLM: 7609387

Informations de publication

Date de publication:
Dec 2023
Historique:
medline: 27 11 2023
pubmed: 8 11 2023
entrez: 7 11 2023
Statut: ppublish

Résumé

Radiomics is an emerging field of artificial intelligence that focuses on the extraction and analysis of quantitative features such as intensity, shape, texture and spatial relationships from medical images. These features, often imperceptible to the human eye, can reveal complex patterns and biological insights. They can also be combined with clinical data to create predictive models using machine learning to improve disease characterization in nuclear medicine. This review article examines the current state of radiomics in nuclear medicine and shows its potential to improve patient care. Selected clinical applications for diseases such as cancer, neurodegenerative diseases, cardiovascular problems and thyroid diseases are examined. The article concludes with a brief classification in terms of future perspectives and strategies for linking research findings to clinical practice.

Identifiants

pubmed: 37935406
doi: 10.1055/a-2191-3271
doi:

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

354-360

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

F.M.M. is medical advisor for NanoMab Technology Ltd. and Advanced Accelerator Applications (AAA) GmbH/Novartis; holds speaker positions at Siemens, GE Healthcare, and Bayer; and has recently received institutional grants from NanoMab Technology Ltd., Siemens, and GE Precision Healthcare LLC. K.-J.L and F.M.M. received honoraria for consultancy service from Telix Pharmaceuticals. P.L. received speaker honoraria from Blue Earth Diagnostics. N.G. received honoraria for lectures from Blue Earth Diagnostics and honoraria for advisory board participation from Telix Pharmaceuticals.

Auteurs

Philipp Lohmann (P)

Institute of Neuroscience and Medicine (INM-3/-4), Forschungszentrum Jülich GmbH, Jülich, Germany.

Ralph Alexander Bundschuh (RA)

Faculty of Medicine, Department of Nuclear Medicine, University of Augsburg, Augsburg, Germany.

Isabelle Miederer (I)

Department of Nuclear Medicine, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.

Felix M Mottaghy (FM)

Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany.
Center for Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany.
Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.

Karl Josef Langen (KJ)

Institute of Neuroscience and Medicine (INM-3/-4), Forschungszentrum Jülich GmbH, Jülich, Germany.
Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany.
Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.

Norbert Galldiks (N)

Faculty of Medicine and University Hospital Cologne, Department of Neurology, University of Cologne, Cologne, Germany.
Institute of Neuroscience and Medicine (INM-3/-4), Forschungszentrum Jülich GmbH, Jülich, Germany.
Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH